Skip to main content
AMAG to expand hematology pipeline with Perosphere acquisition

AMAG Pharmaceuticals announced plans to acquire Perosphere Pharmaceuticals for up to $415 million, and AMAG said the acquisition would expand its hematology pipeline with access to Perosphere's ciraparantag, or PER977, a next-generation anticoagulant reversal drug. Perosphere could receive up to $140 million in payments linked to regulatory milestones achieved in the US and approval from European regulators.

Full Story: